Mach F,Baigent C,Catapano AL,Koskinas KC,Casula M,Badimon L .2020 .ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 41 : 111-88.
Libby P,Buring JE,Badimon L,Hansson GK,Deanfield J,Bittencourt MS .2019 .. Nat Rev Dis Primers, 5 : 56-9.
Ference BA,Ginsberg HN,Graham I,Ray KK,Packard CJ,Bruckert E .2017 .Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 38 : 2459-72.
Arnett DK,Blumenthal RS,Albert MA,Buroker AB,Goldberger ZD,Hahn EJ .2019 .ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 10 : 140.
Ferrieres J,Gorcyca K,Lorga SR .2018 .Lipid lowering therapy and goal achievement in high-risk patients from French general practice. Clin Ther, 40 : 1484-95.
Vrablík M,Šarkanová I,Breciková K,Šedová P,Šatný M,Tichopád A .2023 .Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias. PLoS One, 18 : e0272883.
Ruscica M,Banach M,Sahebkar A,Corsini A,Sirtori CR .2019 .Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother, 20 : 791-803.
Ballantyne CM,Laufs U,Ray KK,Leiter LA,Bays HE,Goldberg AC .2019 .Bempedoic acid plus ezetimibe fixeddose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol, 27 : 593-603.
Sterne JAC,Savović J,Page MJ,Elbers RG,Blencowe NS,Boutron I .2019 .RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 10 : l4898.
Sterne JAC,Hernán MA,Reeves BC,Savović J,Berkman ND,Viswanathan M .2016 .ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ, 10 : i4919.
Laufs U,Ballantyne CM,Banach M,Bays H,Catapano AL,Duell PB .2022 .Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol, 16 : 286-97.
Bays HE,Baum SJ,Brinton EA,Plutzky J,Hanselman JC,Teng R .2021 .Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on lowdensity lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. Am J Prev Cardiol, 8 : 100278.
Migliaccio-Walle K,Elsea D,Gupta A,Sarnes E,Griffith K,Pandey R .2024 .Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US. Atheroscler Plus, 55 : 98-105.
McQueen RB,Baum SJ,Louie MJ,Sasiela WJ,Bilitou A,Shah H .2023 .Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs, 23 : 67-76.
Amore BM,Cramer C,MacDougall D,Emery MG .2023 .The Disposition and Metabolism of Bempedoic Acid, a Potent Inhibitor of ATP Citrate Lyase. Drug Metab Dispos, 51 : 599-609.
Sizar O,Nassereddin A,Talati R.,Ezetimibe R.,Available R. . .StatPearls Publishing; 2024 Jan-. , : .
Ferri N,Ruscica M,Santos RD,Corsini A .2023 .Fixed Combination for the Treatment of Dyslipidaemia. Curr Atheroscler Rep, 25 : 691-699.
Borén J,Chapman MJ,Krauss RM,Packard CJ,Bentzon JF,Binder CJ .2020 .Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 41 : 2313-30.
Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA .2017 .Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376 : 1713-1722.
Goldberg AC,Leiter LA,Stroes ESG,Baum SJ,Hanselman JC,Bloedon LT .2019 .Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA, 322 : 1780-8.
Jadhav SB,Crass RL,Chapel S,Kerschnitzki M,Sasiela WJ,Emery MG .2022 .Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Eur Heart J Cardiovasc Pharmacother, 8 : 578-586.
Oyama K,Giugliano RP,Blazing MA,Park JG,Tershakovec AM,Sabatine MS .2021 .Baseline lowdensity lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in IMPROVE-IT. J Am Coll Cardiol, 78 : 1499-1507.
Kim BK,Hong SJ,Lee YJ,Hong SJ,Yun KH,Hong BK .2022 .Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus highintensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet, 400 : 380-390.
Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA .2017 .Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376 : 1713-22.
Koren MJ,Sabatine MS,Giugliano RP,Langslet G,Wiviott SD,Kassahun H .2017 .Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years from the Open-Label OSLER-1 Extension Study. JAMA Cardiol, 2 : 598-607.
Bhagavathula AS,Al Matrooshi NO,Clark CCT,Rahmani J. Bempedoic,Acid J. Bempedoic .2021 .Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and MetaAnalysis of Randomized Phase II/III trials. Clin Drug Investig, 41 : 19-28.